Status:
UNKNOWN
A Prospective Study of the Relevance of the HLA-G Immune Checkpoint in Cancer Immunotherapy
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Solid Tumor
Eligibility:
All Genders
18+ years
Brief Summary
Therapeutic targeting of immune checkpoints PD-1/PD-L1 and/or CTLA-4 is efficient in several solid cancer subtypes, however only some patients do experience clinical benefit from these treatments. One...
Eligibility Criteria
Inclusion
- Age 18 or older
- Social insurance
- Ability to provide signed consent
- Histologically proven solid cancer (non-small cell lung cancer, urothelial carcinoma, renal cell carcinoma, other)
- Advanced and/or metastatic disease not accessible to local treatment
- At least one target lesion according to iRECIST
- Available fixed tumor sample for immunohistochemistry studies
- Treatment with anti-PD(L)1 immunotherapy with or without anti-CTLA4 immunotherapy
Exclusion
- Women pregnant or breastfeeding
- Inability to consent to this research
- Previous cancer immunotherapy (except BCG instillations for non-muscle infiltrative bladder cancer)
- Patients chronically infected with HIV, HBV or HCV
Key Trial Info
Start Date :
March 10 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 10 2025
Estimated Enrollment :
281 Patients enrolled
Trial Details
Trial ID
NCT04300088
Start Date
March 10 2020
End Date
September 10 2025
Last Update
March 9 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.